Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published on December 21
Government agreements are unlocking $150 billion in domestic pharmaceutical investment. This rare policy-driven catalyst could reshape the entire industry landscape for years to come.
From lab equipment to manufacturing systems, the entire pharmaceutical supply chain stands to benefit. Companies providing essential tools and services are positioned for sustained growth.
Major pharmaceutical companies are committing to unprecedented domestic investment levels. This represents one of the largest industry reshoring initiatives in recent history.
Major pharmaceutical companies have signed voluntary agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and policy concessions. This policy-driven shift is catalysing over $150 billion in new domestic research, development, and manufacturing investments, creating a significant opportunity across the pharmaceutical value chain.
This theme focuses on the complete ecosystem benefiting from pharmaceutical reshoring - from major drug companies to life sciences suppliers, lab equipment providers, and contract research organisations. The investments represent a strategic shift toward domestic bio-industrial capacity, driven by government negotiations rather than traditional regulation.
These companies were handpicked by professional analysts as the key players and beneficiaries of this massive investment cycle. The selection includes pharmaceutical giants signing the agreements, essential suppliers providing equipment and services, and specialised firms supporting the expanded domestic manufacturing and research infrastructure.
This basket's total market capitalisation is 1,448,871.6830000002 and is anchored by several very large-cap constituents, concentrating weight at the top.
MRK: $250.91B
AMGN: $176.29B
TMO: $213.34B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
13 of 15 assets in this group are rated Buy by professional analysts.
